pOptiVEC™-TOPO®
TA Cloning Kit

For TOPO® Cloning of PCR products into a bicistronic vector

Catalog nos. 12744-017, 12745-014

Version A
27 November 2006
25-0977

Table of Contents

Kit Contents and Storage iv
Accessory Products vi
Overview 1
Methods 4
Designing PCR Primers 4
Producing PCR Products 6
Setting Up the TOPO® Cloning Reaction 8
Transforming One Shot® Competent *E. coli* 10
Analyzing Positive Clones 12
Next Steps 13
Troubleshooting 14
Appendix 16
Performing the Control Reactions 16
Addition of 3′ A-Overhangs Post-Amplification 18
Map and Features of pOptiVEC™-TOPO® 19
Recipe 21
Technical Support 22
Purchaser Notification 23
Product Qualification 26
References 27
Notes 28

Kit Contents and Storage

Shipping and Storage

The pOptiVEC™-TOPO® TA Vector Kit is shipped on dry ice. Each kit contains two boxes as described below. Upon receipt, store boxes as detailed below.

Box	Item	Storage
1	pOptiVEC™-TOPO® TA Cloning Reagents	-20°C
2	One Shot® TOP10 Chemically Competent *E. coli*	-80°C

TOPO® TA Cloning Reagents

The pOptiVEC™-TOPO® TA cloning reagents (Box 1) are listed below. **Note that the user must supply *Taq* polymerase**. **Store the contents of Box 1 at -20°C.**

Item	Concentration	Amount
pOptiVEC™ vector, TOPO® adapted	5-10 ng linearized plasmid DNA in: 50% glycerol 50 mM Tris-HCl, pH 7.4 1 mM EDTA 1mM DTT 0.1% Triton X-100 100 µg/ml BSA 30 µm phenol red	10 µl
10X PCR Buffer	100 mM Tris-HCl, pH 8.3 (at 42°C) 500 mM KCl 25 mM $MgCl_2$ 0.01% gelatin	100 µl
dNTP Mix	12.5 mM dATP 12.5 mM dCTP 12.5 mM dGTP 12.5 mM dTTP neutralized at pH 8.0 in water	10 µl
Salt Solution	1.2 M NaCl 0.06 M $MgCl_2$	50 µl
Sterile Water	---	1 ml
Control PCR template	50 ng/µl in TE buffer, pH 8.0	10 µl
Control PCR primers	100 ng/µl each in TE buffer, pH 8.0	10 µl
CMV forward sequencing primer	100 ng/µl in TE buffer, pH 8.0	20 µl
EMCV IRES reverse sequencing primer	100 ng/µl in TE buffer, pH 8.0	20 µl

Continued on next page

Kit Contents and Storage, continued

Primers

The pOptiVEC™-TOPO® TA Vector Kit contains the following primers to sequence your insert.

Primer	Sequence
CMV forward	5′-CGCAAATGGGCGGTAGGCGTG-3′
EMCV IRES reverse	5′- CCTTATTCCAAGCGGCTTCG-3′

One Shot® TOP10 Reagents

The following reagents are included in the One Shot® TOP10 Chemically Competent *E. coli* kit (Box 2). Transformation efficiency is ≥ 1 x 10^9 cfu/µg plasmid DNA. **Store the contents of Box 2 at -80°C**.

Item	Concentration	Amount
TOP10 *E. coli*	---	11 x 50 µl
pUC19 Control DNA	10 pg/µl in 5 mM Tris-HCl, 0.5 mM EDTA, pH 8	50 µl
S.O.C. Medium	2% Tryptone 0.5% Yeast extract 10 mM NaCl 2.5 mM KCl 10 mM $MgCl_2$ 10 mM $MgSO_4$ 20 mM glucose	6 ml

Genotype of TOP10 Strain

F^- *mcr*A Δ(*mrr*-*hsd*RMS-*mcr*BC) Φ80*lac*ZΔM15 Δ*lac*X74 *rec*A1 *ara*D139 Δ(*ara*-*leu*)7697 *gal*U *gal*K *rps*L (Str^R) *end*A1 *nup*G

Accessory Products

Additional Products

The products listed in this section are available from Invitrogen and may be used with the pOptiVEC™-TOPO® TA Cloning Kit. Ordering information is provided below.

Product	Amount	Catalog no.
Platinum® *Taq* DNA Polymerase	100 reactions	10966-018
	250 reactions	10966-026
	500 reactions	10966-034
Platinum® *Taq* DNA Polymerase High Fidelity	100 units	11304-011
One Shot® TOP10 Chemically Competent *E. coli*	10 reactions	C4040-10
	20 reactions	C4040-03
One Shot® TOP10 Electrocompetent *E. coli*	10 reactions	C4040-50
	20 reactions	C4040-52
LB Media	500 ml	10855-021
Ampicillin	5 g	Q100-16
PureLink™ HQ Plasmid Miniprep Kit	100 reactions	K2100-01
S.N.A.P.™ Midiprep DNA Isolation Kit	20 reactions	K1910-01
E-Gel® 1.2% Starter Pak (6 gels + Powerbase™)	1 kit	G6000-01
E-Gel® 1.2% 18 Pak	18 gels	G5018-01
E-Gel® CloneWell 0.8% SYBR Safe™ Gel and iBase™ Starter Kit	1 kit	G6400ST
PureLink™ Quick Gel Extraction System	1 kit	K2100-12
PCR Optimizer™ Kit	1 kit	K1220-01
OptiCHO™ Expression Kit	1 kit	12745-014
DG44 Cells	1 vial	12609-012
CD DG44 Medium	1000 ml	12610-010
FreeStyle™ MAX Transfection Reagent	1 ml	16447-100
OptiPRO™ SFM	100 ml	12309-050
CD OptiCHO™ Medium	1000 ml	12681-011
Pluronic® F-68, 10%	100 ml	24040-032
L-glutamine, 200 mM	100 ml	25030-081

Overview

Description

The pOptiVEC™-TOPO® vector is a TOPO®-adapted bicistronic plasmid that allows rapid cloning of a PCR product containing a mammalian secretion signal and the gene of interest downstream of the CMV promoter. In the pOptiVEC™-TOPO® vector, the transcription of the gene of interest is separated from the dihydrofolate reductase (DHFR) auxotrophic selection marker by an internal ribosome entry site (IRES), allowing transcription of the gene of interest and the selection marker on the same mRNA.

Using the OptiCHO™ Expression System (available separately from Invitrogen, see page vi), you will transfect your pOptiVEC™-TOPO® plasmid construct into CHO-derived, DHFR-negative DG44 cells to create a stable cell line by selection in medium lacking hypoxanthine and thymidine (HT). You may then optimize your protein production by genomic amplification and/or dilution to obtain a clone that produces high amounts of your secreted protein of interest (Werner, 2005). More information on these procedures can be found in the OptiCHO™ Expression Kit manual.

Features of the Vector

The pOptiVEC™-TOPO® vector contains the following elements:

- Human cytomegalovirus (CMV) immediate-early promoter/enhancer for high-level gene expression in a wide range of mammalian cells
- TOPO® Cloning site for rapid and efficient cloning of *Taq*-amplified PCR products
- Internal Ribosome Entry Site (IRES) from the encephalomyocarditis virus (EMCV) for cap-independent translation of DHFR
- Dihydrofolate reductase (DHFR) gene for auxotrophic selection of transfected DG44 cells and for genomic amplification of stable cell lines using methotrexate (MTX)
- The Herpes Simplex Virus thymidine kinase polyadenylation signal for proper termination and processing of the recombinant transcript
- pUC origin for high copy replication and maintenance of the plasmid in *E. coli*
- Ampicillin (*bla*) resistance gene for selection in *E. coli*

For a map and features of the pOptiVEC™-TOPO® vector, see pages 19-20.

Continued on next page

How TOPO® Works

The pOptiVEC™-TOPO® vector is supplied linearized with:

- Single 3´ thymidine (T) overhangs for TA Cloning®
- Topoisomerase covalently bound to the vector (this is referred to as "activated" vector)

Taq polymerase has a nontemplate-dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. The linearized vector supplied in this kit has single, overhanging 3´ deoxythymidine (T) residues. This allows PCR inserts to ligate efficiently with the vector.

Topoisomerase I from Vaccinia virus binds to duplex DNA at specific sites and cleaves the phosphodiester backbone after 5′-CCCTT in one strand (Shuman, 1991). The energy from the broken phosphodiester backbone is conserved by formation of a covalent bond between the 3′ phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of topoisomerase I. The phospho-tyrosyl bond between the DNA and enzyme can subsequently be attacked by the 5′ hydroxyl of the original cleaved strand, reversing the reaction and releasing topoisomerase (Shuman, 1994). TOPO® Cloning exploits this reaction to efficiently clone PCR products.



Once the PCR product is cloned into the pOptiVEC™-TOPO® vector and the transformants are analyzed for correct orientation and reading frame, the expression plasmid may be transfected into the CHO derived DG44 cells using the OptiCHO™ Expression Kit for expression of your secreted protein of interest. For more information, refer to the OptiCHO™ Expression Kit manual.

EMCV IRES

The internal ribosome entry site (IRES) from encephalomyocarditis virus (EMCV) allows cap-independent translation initiation of the DHFR selection gene. The EMCV IRES allows expression of the gene of interest and the selection marker from a single bicistronic mRNA (Gurtu *et al.*, 1996; Rees *et al.*, 1996).

Continued on next page

DHFR

Dihydrofolate reductase (DHFR) catalyzes the reduction of 5, 6-dihydrofolate to 5, 6, 7, 8-tetrahydrofolate, which is essential for DNA synthesis. CHO-derived DG44 cells lack DHFR activity and must be propagated in medium containing the purine precursors hypoxanthine and thymidine (HT) unless the cells are stably transfected with a vector that expresses DHFR. Auxotrophic selection eliminates the need to maintain selection pressure using antibiotics, which could potentially contaminate the production of your protein of interest.

DHFR can also function as a genomic amplification marker for your gene of interest using methotrexate (MTX) selection (Kaufman *et al.*, 1985). See the OptiCHO™ Expression Kit manual for more details on this procedure.

Experimental Outline

To TOPO® Clone your gene of interest into pOptiVEC™-TOPO®, you will perform the following steps:

1. Generate a PCR product containing a mammalian secretion signal and your gene of interest with *Taq* polymerase.
2. TOPO® Clone your PCR product into the pOptiVEC™-TOPO® vector and use the reaction to transform One Shot® TOP10 Chemically Competent *E. coli*
3. Pick colonies, isolate plasmid DNA, and screen for insert directionality by sequencing expression clones with the primers provided in the kit.

The following sections of this manual provide instructions and guidelines for these steps.

Methods

Designing PCR Primers

Introduction

TOPO® Cloning provides a highly efficient, 5-minute, one-step cloning strategy ("TOPO® Cloning") for the direct insertion of *Taq* polymerase-amplified PCR products into a plasmid vector. No ligase, post-PCR procedures, or PCR primers containing specific sequences are required. The section below will help you design primers to produce your PCR product for cloning into the pOptiVEC™-TOPO®vector.

Points to Consider When Designing PCR Primers

To obtain the pOptiVEC™-TOPO expression construct containing your gene of interest, your PCR primer design must include a Kozak consensus sequence and a mammalian secretion signal upstream of your gene of interest, and a stop codon at the end of your gene of interest. See below for more information.

Kozak Consensus Sequence

You gene of interest must contain a Kozak translation initiation sequence with an ATG initiation codon for proper initiation of translation (Kozak, 1987; Kozak, 1990; Kozak, 1991). An example of a Kozak consensus sequence is provided below. The ATG initiation codon is shown underlined.

(G/A)NNATG**G**

Other sequences are possible, but the G or A at position -3 and the G at position +4 are the most critical for function (shown in bold).

Secretion Signal

Since your protein of interest will be secreted from mammalian DG44 cells, your gene of interest must include a mammalian secretion signal. To direct secretion of your protein of interest, you can include the endogenous secretion signal of your protein of interest, or add one such as the murine Ig κ-chain leader sequence (Coloma *et al.*, 1992) using PCR.

Note

Do not add 5′ phosphates to your primers for PCR, because the synthesized PCR product will not ligate into the vector.

Cloning efficiencies may vary depending on the primer nucleotide sequences.

Continued on next page

Designing PCR Primers, continued

TOPO® Cloning Site

Use the diagram below to help you design your PCR product for TOPO® Cloning into pOptiVEC™-TOPO®. The complete vector sequence is available from www.invitrogen.com or by contacting Technical Service (page 22).



Producing PCR Products

Introduction

After you have designed primers to amplify your gene of interest, you are ready to produce your PCR product for TOPO® Cloning into the pOptiVEC™-TOPO® vector.

Materials Supplied by User

You will need the following reagents and equipment:

- *Taq* polymerase, such as Platinum® *Taq* (see page vi)
- Thermocycler
- DNA template
- Primers for PCR product

Polymerase Mixtures

You may use an enzyme mixture containing *Taq* polymerase and a proofreading polymerase; however *Taq* must be used in excess of 10:1 to ensure the presence of 3′ A-overhangs on the PCR product. We recommend using Platinum® *Taq* DNA Polymerase High Fidelity available from Invitrogen (see page vi for ordering information).

If you use polymerase mixtures that do not have enough *Taq* polymerase or use a proofreading polymerase only, you can add 3′ A-overhangs after amplification using the method on page 18.

Producing PCR Products

1. Set up the following reaction in a 50 µl volume. Use less DNA if you are using plasmid DNA as a template and more DNA if you are using genomic DNA as a template.

Reagent	Amount
DNA template	10-100 ng
10X PCR Buffer	5 µl
50 mM dNTPs	0.5 µl
PCR Primers	100-200 ng each
Sterile Water	to final volume of 49 µl
Taq polymerase (1 unit/µl)	1 µl
Total Volume	**50 µl**

2. Perform amplification using the cycling parameters suitable for your primers and template. Be sure to include a 7-30 minute extension at 72° after the last cycle to ensure that all PCR products are full-length and 3′ adenylated.
3. Use agarose gel electrophoresis to verify the quality of your PCR product. You should see a single, discrete band of the correct size. If you do not see a single band, refer to the **Note** on the next page.

Continued on the next page



Note

If you do not obtain a single, discrete band from your PCR reaction, try the following:

- The PCR Optimizer™ Kit (Catalog no. K1220-01) from Invitrogen can help you optimize your PCR to eliminate multiple bands and smearing.
- Gel-purify your fragment before performing the TOPO® Cloning reaction using the E-Gel® CloneWell system or PureLink™ Gel Extraction Kit, available separately from Invitrogen. See page vi for more information.

Alternatively, refer to Current Protocols in Molecular Biology, Unit 2.6 (Ausubel *et al.*, 1994) for other common protocols for isolating DNA fragments.

Setting Up the TOPO® Cloning Reaction

Introduction

Once you have produced the desired PCR product, you are ready to TOPO® Clone it into the pOptiVEC™-TOPO® vector and use this plasmid for transformation of competent *E. coli*. It is important to have everything you need to set up the reaction so that you can obtain the best results. We suggest that you read this entire section and the next section about transformation before beginning. If this is the first time you have TOPO® Cloned, perform the control reactions detailed on pages 16-17 in parallel with your samples.



Note

We have found that including salt (200 mM NaCl, 10 mM $MgCl_2$) in the TOPO® Cloning reaction increases the number of transformants 2- to 3-fold. In addition, incubating the reaction mixture for greater than 5 minutes in the presence of salt can also increase the number of transformants. This is in contrast to earlier experiments **without salt** where the number of transformants decreases as the incubation time increases beyond 5 minutes.

Including salt in the TOPO® Cloning reaction allows for longer incubation times because it prevents topoisomerase I from rebinding and potentially nicking the DNA after ligating the PCR product and dissociating from the DNA. The result is more intact molecules leading to higher transformation efficiencies.

Using Salt in the TOPO® Cloning Reaction

You will perform TOPO® Cloning in a reaction buffer containing salt (*i.e.* using the stock salt solution provided in the kit). Note that the amount of salt added to the TOPO® Cloning reaction varies depending on whether you plan to transform chemically competent cells (provided) or electrocompetent cells (see page vi for ordering information).

- If you are transforming chemically competent *E. coli* (included with the kit), use the stock Salt Solution as supplied, and set up the TOPO® Cloning reaction as directed on the next page.
- If you are transforming electrocompetent *E. coli* (available separately from Invitrogen; see page vi), the amount of salt in the TOPO® Cloning reaction must be reduced to 50 mM NaCl, 2.5 mM $MgCl_2$ to prevent arcing during electroporation. Dilute the stock Salt Solution 4-fold with water to prepare a 300 mM NaCl, 15 mM $MgCl_2$ Dilute Salt Solution. Use the Dilute Salt Solution to set up the TOPO® Cloning reaction as directed on the next page.

Continued on next page

Setting Up the TOPO® Cloning Reaction, continued

Materials Needed

You should have the following materials on hand before beginning:

- Your PCR product (freshly prepared)
- pOptiVEC™-TOPO® vector
- Salt Solution or Dilute Salt Solution (see previous page)
- Sterile Water

Performing the TOPO® Cloning Reaction

The table below describes how to set up your TOPO® Cloning reaction (6 µl) to use for transformation of either chemically competent or electrocompetent *E. coli*.

Note: The red color of the TOPO® vector solution is normal and is used to visualize the solution.

Reagent	Chemically Competent *E. coli*	Electrocompetent *E. coli*
PCR Product	0.5 to 4 µl	0.5 to 4 µl
Salt Solution	1 µl	--
Dilute Salt Solution	--	1 µl
Sterile Water	Add to total volume of 5 µl	Add to total volume of 5 µl
TOPO® Vector	1 µl	1 µl
Final Volume	**6 µl**	**6 µl**

*Store all reagents at -20°C when finished. Salt solution and water can be stored at room temperature or +4°C.

1. Mix reaction gently and incubate for 5 minutes at room temperature (22°-23°C).

   Note: For most applications, 5 minutes will yield a sufficient number of colonies for analysis. The length of the TOPO® Cloning reaction can be varied from 30 seconds to 30 minutes. For routine subcloning of PCR products, 30 seconds may be sufficient. For larger PCR products (>1 kb), increasing the reaction time may yield more colonies.

2. Place the reaction on ice and proceed to Transforming One Shot® Competent *E. coli*, next page.

   Note: You may store the TOPO® Cloning reaction overnight at -20°C.

Transforming One Shot® Competent *E. coli*

Introduction

Once you have performed the TOPO® Cloning reaction you are ready to use your construct to transform competent *E. coli*. One Shot® TOP10 Chemically Competent *E. coli* are included with the kit (Box 2) to facilitate transformation. You may also transform One Shot® Electrocompetent cells if desired (see page vi for ordering information). Protocols for transforming chemically competent and electrocompetent *E. coli* are provided in this section.

Selecting a One Shot® Chemical Transformation Protocol

Two protocols are provided to transform One Shot® TOP10 chemically competent *E. coli*. Consider the following factors and choose the protocol that best suits your needs.

If you wish to…	Then use the…
Maximize the number of transformants	Regular chemical transformation protocol, page 11.
Clone large PCR products (>1000 bp)	
Obtain transformants as quickly as possible	Rapid chemical transformation protocol, page 11. **Note:** This procedure is less efficient; the total number of transformants obtained may be lower than that obtained with the regular chemical transformation protocol.

Materials Needed

In addition to general microbiological supplies (*i.e.* plates, spreaders), you will need the following:

- TOPO® Cloning reaction (From Step 2, previous page)
- One Shot® TOP10 *E. coli*, either chemically competent (supplied with the kit, Box 2) or electrocompetent (purchased separately, see page vi)
- S.O.C. Medium (supplied with the kit, Box 2)
- pUC19 positive control (supplied with the kit, Box 2)
- 42°C water bath (chemically competent cells only)
- Electroporator with cuvettes (electrocompetent cells only)
- 15 ml sterile, snap cap plastic culture tubes (electrocompetent cells only)
- For each transformation reaction, 2 selective LB plates containing 100 µg/ml ampicillin. See page 21 for a recipe to prepare selective LB
- 37°C shaking and non-shaking incubators

Continued on next page

Preparing for Transformation

For each transformation, you will need one vial of One Shot® competent cells and two selective LB plates.

- Equilibrate a water bath to 42°C if using chemically competent *E. coli*, or set up your electroporator if using electrocompetent *E. coli*
- Warm the vial of S.O.C. Medium to room temperature
- Warm selective LB plates at 37°C for 30 minutes
- Thaw one vial of One Shot® cells **on ice** for each transformation

One Shot® Chemical Transformation Protocol

Use the following protocol to transform One Shot® TOP10 chemically competent *E. coli*.

1. Add 2 µl of the TOPO® Cloning reaction into a vial of One Shot® Chemically Competent *E. coli* with a sterile pipette tip and mix gently. Do not mix by pipetting up and down.

   Note: If you are using the pUC19 control plasmid for transformation, use 1 µl (10 pg).
2. Incubate cells/plasmid mix on ice for 5-30 minutes.

   Note: Longer incubations on ice seem to have a minimal effect on transformation efficiency.
3. Heat-shock the cells for 30 seconds at 42°C without shaking.
4. Immediately transfer the tubes to ice.
5. Add 250 µl of room temperature S.O.C. Medium.
6. Cap the tube tightly and shake the tube horizontally at 200 rpm in a 37°C shaking incubator for 1 hour.
7. Spread 10-50 µl from each transformation on a prewarmed selective LB plate. To ensure even spreading of small volumes, you may add 20 µl of S.O.C. Medium to the transformation mixture. We recommend that you plate two different volumes to ensure that at least one plate contains well-spaced colonies. Incubate plates overnight at 37°C.

Rapid One Shot® Chemical Transformation Protocol

Use the alternative protocol below to rapidly transform One Shot® TOP10 chemically competent *E. coli*. Before beginning, prewarm LB plates containing 100 µg/ml ampicillin at 37°C for 30 minutes.

1. Add 4 µl of the TOPO® Cloning reaction into a vial of One Shot® TOP10 chemically competent *E. coli* and mix gently. Do not mix by pipetting up and down.
2. Incubate reaction on ice 5 minutes.
3. Spread 50 µl of cells on a prewarmed selective LB plate and incubate overnight at 37°C.

Analyzing Positive Clones

Introduction

After transformation of your pOptiVEC™ construct into *E. coli*, you will select and analyze several colonies by sequencing using the specific primers included in the kit to determine the orientation of the insert.

Analyzing Positive Clones

1. Pick 10 colonies and culture them overnight in LB medium containing 100 µg/ml ampicillin.
2. Isolate plasmid DNA using your method of choice. If you need ultra-pure plasmid DNA for automated or manual sequencing, we recommend using Invitrogen's PureLink™ HQ Mini Plasmid Purification Kit. See page vi for ordering information.
3. Analyze plasmid DNA by sequencing (see below).

Sequencing

To confirm that your gene of interest is in the correct orientation, you may sequence your expression construct using the CMV forward and EMCV IRES reverse primers included with the kit. Refer to page v for the sequences of the primers and the diagram on page 5 for the location of the primer binding sites.

Long-Term Storage

Once you have identified the correct clone, be sure to purify the colony and make a glycerol stock for long-term storage.

1. Streak the original colony out for single colonies on an LB plate containing 100 µg/ml ampicillin.
2. Isolate a single colony and inoculate into 1-2 ml of LB containing 100 µg/ml ampicillin.
3. Grow at 37°C with shaking until culture reaches stationary phase.
4. Mix 0.85 ml of culture with 0.15 ml of sterile glycerol.
5. Transfer to a cryovial and store at -80°C.

We also recommend that you store a stock of plasmid DNA at -20°C.

Next Steps

Introduction

Once you obtain the correct pOptiVEC™-TOPO plasmid construct, you will linearize and purify the plasmid prior to transfection into DG44 cells using the OptiCHO™ Expression Kit (supplied with cat. no. 12745-014 or available separately; see page vi for ordering information).

The OptiCHO™ Expression Kit includes DG44 cells, which are dihydroxyfolate reductase (DHFR)-negative, CHO-derived cells that are adapted to high density, serum-free suspension culture and are capable of producing high levels of recombinant protein The OptiCHO™ Expression Kit includes FreeStyle™ MAX Reagent, which provides high transfection efficiency of the pOptiVEC™ construct into DG44 cells, as well as growth and selection media and additives supporting DG44 cell growth and protein expression.

Plasmid Preparation

The pOptiVEC™-TOPO® plasmid construct must be clean, sterile and free from contamination with phenol and sodium chloride for transfection into DG44 cells. Contaminants may kill the cells, and salt will interfere with lipid complexing, decreasing transfection efficiency. We recommend isolating plasmid DNA using the S.N.A.P. Midiprep DNA Isolation Kit (see page vi for ordering information).

Linearizing the Plasmid

Prior to using the OptiCHO™ Expression Kit to transfect DG44 cells with your pOptiVEC™ construct, you need to linearize the plasmid. While linearizing your vector may not improve transfection efficiency, it increases the chances that the vector integrates into the host cell genome without disrupting the gene of interest or other elements required for expression in mammalian cells.
We suggest using *Pvu* I, which cuts once in the ampicillin resistance gene. Other unique restriction sites are possible. A complete restriction map of pOptiVEC™ TOPO® is available at www.invitrogen.com. **Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.**

After digestion, precipitate the DNA and resuspend pellet in sterile water and re-quantify using your method of choice.

Troubleshooting

Introduction

The table below lists some potential problems solutions that may help you troubleshoot your TOPO® Cloning.

Problem	Possible Cause	Solution
Few or no colonies obtained from sample reaction, but transformation control yielded colonies	Incomplete extension during PCR	Include a final extension step of 7-30 minutes during PCR. Longer PCR products will need a longer extension time.
	Excess or dilute PCR product used in the TOPO® Cloning reaction	Reduce or concentrate the amount of PCR product.
	PCR primers contain 5′ phosphates	Do not add 5′ phosphates to your PCR primers.
	Used a proofreading polymerase or a *Taq*/proofreading polymerase mixture for PCR	Use *Taq* polymerase to add 3′A-overhangs to your PCR product by following the method on page 18.
	Large PCR product	• Increase the amount of PCR product used in the TOPO® Cloning reaction. • Increase the incubation time of TOPO® Cloning reaction from 5 minutes to 30 minutes. • Gel-purify the PCR product to remove primer-dimers or other artifacts.
	PCR reaction contains artifacts (i.e. not a single band on an agarose gel)	• Optimize your PCR conditions. • Gel-purify your PCR product.
	PCR product does not contain sufficient 3′A-overhangs even though you used *Taq* polymerase	• Increase the final extension time to ensure that all 3′ ends are adenylated. *Taq* polymerase is most efficient at adding a non-template 3′A next to a C, and less efficient at adding a nontemplate 3′ A next to another A (Brownstein *et al.*, 1996). • You may redesign your primers so that they contain a 5′ G instead of a 5′ T.

Continued on next page

Troubleshooting, continued

Problem	Possible Cause	Solution
Large number of incorrect inserts cloned	PCR cloning artifacts	• Gel-purify your PCR product to remove primer-dimers and other artifacts. • Optimize your PCR conditions. • Include a final extension step of 7-30 minutes during PCR.
Few or no colonies obtained from sample reaction and the transformation control gave no colonies	One Shot® competent *E. coli* stored incorrectly	• Store One Shot® competent *E. coli* at -80°C. • If you are using another *E. coli* strain, follow the manufacturer's instructions.
	Insufficient amount of *E. coli* plated	Increase the amount of *E. coli* plated.
	Transformants plated on selective plates with the wrong antibiotic	Use LB ampicillin plates for selection.

Appendix

Performing the Control Reactions

Introduction

We recommend performing the following control TOPO® Cloning reactions the first time you use the kit to help you evaluate your results. Performing the control reactions involves producing a control PCR product expressing the LacZα fragment using the reagents included in the kit. Successful TOPO® Cloning of the control PCR product in either direction will yield > 85% blue colonies on LB plates containing ampicillin and X-gal.

Before Starting

The following reagents should be prepared before performing the control reaction:

- Prepare stock X-gal solution (40 mg/ml X-gal in dimethylformamide)
- For each transformation, you will need two LB plates containing 100 μg/ml ampicillin and X-gal

To add X-gal to previously made LB plates, warm the plate to 37°C, add 40 μl of the stock X-gal solution with a sterile pipette, spread evenly and let dry 15 minutes. Store plates at +4°C, protected from light.

Producing the Control PCR Product

1. In a 0.5 ml microcentrifuge tube, set up the following reaction in a 50 μl volume. Overlay reaction with 1 drop of mineral oil if required.

Reagent	Amount
Control DNA Template	1 μl
10X PCR Buffer	5 μl
50 mM dNTPs	0.5 μl
Control PCR Primers (0.1 μg/μl each)	1 μl
Sterile Water	41.5 μl
Taq polymerase (1 unit/μl)	1 μl
Total Volume	50 μl

2. Amplify the control PCR product using the following cycling parameters:

Step	Time	Temp.	Cycles
Initial Denaturation	2 min.	94°C	1X
Denaturation	1 min.	94°C	25X
Annealing	1 min.	60°C	
Extension	1 min.	72°C	
Final Extension	7 min.	72°C	1X

3. Remove 10 μl from the reaction and analyze by agarose gel electrophoresis. A discrete 500 bp band should be visible.

Continued on next page

Performing the Control Reactions, continued

Control TOPO® Cloning Reactions

Using the control PCR product generated in the steps above and the control vector, set up two 6 µl TOPO® Cloning reactions as described below:

Reagent	"Vector Only"	"Vector + PCR Insert"
Control PCR Product	--	1 µl
Sterile Water	4 µl	3 µl
Salt Solution or Dilute Salt Solution	1 µl	1 µl
pOptiVEC™-TOPO® vector	1 µl	1 µl

1. Incubate at room temperature for 5 minutes and place on ice.
2. Use 2 µl of the reaction to transform two separate vials of One Shot® competent cells using the procedure on page 10.
3. Spread 10-50 µl of each transformation mix onto LB plates containing 100 µg/ml ampicillin and X-gal. When plating small volumes, add 20 µl of S.O.C. Medium to ensure even spreading. Be sure to plate two different volumes to ensure that at least one plate has well-spaced colonies.
4. Incubate plates overnight at 37°C.

What You Should See

The "vector + PCR insert" reaction should produce hundreds of colonies. Greater than 85% of these will be blue.

The "vector only" reaction should yield very few colonies (<15% of the vector + PCR insert plate) and these should be white.

Transformation Control

pUC19 plasmid is included to check the transformation efficiency of the One Shot® competent cells. Transform one vial of One Shot® TOP10 cells with 10 pg of pUC19 using the protocol on page 10. Plate 10 µl of the transformation reaction plus 20 µl of S.O.C. on LB plates containing 100 µg/ml ampicillin. The transformation efficiency should be 1×10^9 cfu/µg DNA.

Addition of 3' A-Overhangs Post-Amplification

Introduction

TOPO® Cloning DNA amplified by proofreading polymerases into TOPO® Cloning vectors often results in very low cloning efficiencies. Proofreading polymerases remove the 3´ A-overhangs necessary for TOPO® Cloning. A method for adding 3'As post-amplification is provided below.

Before Starting

You will need the following items:

- *Taq* polymerase
- A heat block equilibrated to 72°C
- Phenol-chloroform (optional)
- 3 M sodium acetate (optional)
- 100% ethanol (optional)
- 80% ethanol (optional)
- TE buffer (optional)

Procedure

This is just one method for adding 3´ A-overhangs. Other protocols may be suitable.

1. After amplification with a proofreading polymerase, place vials on ice and add 0.7-1 unit of *Taq* polymerase per tube. Mix well. It is not necessary to change the buffer.
2. Incubate at 72°C for 8-10 minutes (do not cycle).
3. Place the vials on ice. The DNA amplification product is now ready for ligation into pOptiVEC™-TOPO®.

   Note: If you plan to store your sample overnight before proceeding with TOPO® Cloning, extract your sample with an equal volume of phenol-chloroform to remove the polymerases. Ethanol-precipitate the DNA and resuspend in TE buffer using the starting volume of the PCR.

Map and Features of pOptiVEC™-TOPO®

Map

The map below shows the elements of the pOptiVEC™-TOPO® vector. **The complete sequence is available for downloading from www.invitrogen.com or by contacting Technical Service (page 22).**



Comments for pOptiVEC™-TOPO® 4402 nucleotides

CMV promoter:	36-623
CMV forward primer binding site:	573-593
TOPO® cloning site:	730
EMCV IRES:	772-1359
EMCV IRES reverse primer binding site:	810-829
DHFR:	1372-1935
TK polyadenylation signal:	1975-2247
pUC origin (c):	2609-3282
Ampicillin (*bla*) resistance gene (c):	3424-4284
bla promoter (c):	4279-4383

(c) = complementary strand

Continued on next page

Map and Features of pOptiVEC™-TOPO®, continued

Features

The pOptiVEC™-TOPO® vector contains the following elements. Features have been functionally tested, and the vectors have been fully sequenced.

Feature	Benefit
Human cytomegalovirus (CMV) immediate-early promoter/enhancer	Allows efficient, high-level expression of your recombinant protein (Andersson *et al.*, 1989; Boshart *et al.*, 1985; Nelson *et al.*, 1987)
CMV forward primer	Allows sequencing of the insert
TOPO® Cloning site	Allows insertion of your PCR product
EMCV IRES reverse primer	Allows sequencing of the insert
Internal Ribosome Entry Site (IRES) from the Encephalomyocarditis virus (EMCV)	Allows cap-independent translation of DHFR (Gurtu *et al.*, 1996; Rees *et al.*, 1996)
Dihydrofolate reductase (DHFR) gene	Allows auxotrophic selection of transfected DG44 cells and for genomic amplification of stable cell lines using methotrexate (MTX) (Kaufman *et al.*, 1985)
Herpes Simplex Virus Thymidine Kinase (TK) polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA (Cole & Stacy, 1985)
pUC origin	Allows high-copy number replication and growth in *E. coli*
Ampicillin (*bla*) resistance gene (β-lactamase)	Allows selection of transformants in *E. coli*

Recipe

LB (Luria-Bertani) Medium and Plates

Composition:

1.0% Tryptone

0.5% Yeast Extract

1.0% NaCl

pH 7.0

1. For 1 liter, dissolve 10 g tryptone, 5 g yeast extract, and 10 g NaCl in 950 ml deionized water.
2. Adjust the pH of the solution to 7.0 with NaOH and bring the volume up to 1 liter.
3. Autoclave on liquid cycle for 20 minutes at 15 psi. Allow solution to cool to 55°C and add antibiotic if needed.
4. Store at room temperature or at +4°C.

LB agar plates

1. Prepare LB medium as above, but add 15 g/L agar before autoclaving.
2. Autoclave on liquid cycle for 20 minutes at 15 psi.
3. After autoclaving, cool to ~55°C, add antibiotic if needed, and pour into 10 cm plates.
4. Let harden, then invert and store at +4°C.

Continued on next page

Technical Support

Web Resources

Visit the Invitrogen website at **www.invitrogen.com** for:

- Technical resources, including manuals, vector maps and sequences, application notes, MSDSs, FAQs, formulations, citations, handbooks, etc.
- Complete technical support contact information
- Access to the Invitrogen Online Catalog
- Additional product information and special offers

Contact Us

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our website (www.invitrogen.com).

Corporate Headquarters:
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_support@invitrogen.com

Japanese Headquarters:
Invitrogen Japan
LOOP-X Bldg. 6F
3-9-15, Kaigan
Minato-ku, Tokyo 108-0022
Tel: 81 3 5730 6509
Fax: 81 3 5730 6519
E-mail: jpinfo@invitrogen.com

European Headquarters:
Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com

MSDS

MSDSs (Material Safety Data Sheets) are available on our website at www.invitrogen.com/msds.

Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Service Representatives.

Invitrogen warrants that all of its products will perform according to specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Service Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

Purchaser Notification

Limited Use Label License No: 5 Invitrogen Technology

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com

Limited Use Label License No. 28: CMV Promoter

The use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.

Limited Use Label License No 118: TOPO® Cloning Products

The TOPO® Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,766,891, 6,548,277 and/or other pending U.S. and foreign patent applications licensed to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Continued on next page

Limited Use Label License No 120: TA® Cloning Products

The TA® Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,487,993, and 5,827,657, and/or pending foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Limited Use Label License No. 298: IRES

This product is licensed under U.S. Patent No. 4,937,190 for use in research by laboratories of academic, government, industrial and/or clinical institutions engaged in the investigation of biological or biochemical processes, including applications for the enhancement of translation in living cells, but specifically excluding applications in cell-free systems or use in diagnostic or therapeutic applications or for which FDA approval is required. For information on licensing for uses other than those permitted above, contact EMD Biosciences, 441 Charmany Drive, Madison, WI, 53719 USA. Tel. (608) 442-4006.

Product Qualification

Introduction

This section describes the criteria used to qualify the components of the pOptiVEC™-TOPO® TA Kit.

Vector

- Prior to adaptation with topoisomerase I, the parental supercoiled vectors are qualified by restriction enzyme digestion to verify identity and structure.
- Each control vector is qualified by restriction enzyme digestion to verify identity and structure.

TOPO® Cloning Efficiency

After adaptation with topoisomerase, each lot of the pOptiVEC™-TOPO® vector is functionally qualified using the control reagents included in the kit. Under conditions described on pages 16-17, a 500-bp control PCR product is amplified, TOPO® Cloned into the vector, and transformed into One Shot® TOP 10 Chemically Competent *E. coli* included with the kit.

Each lot of vector should yield greater than 85% cloning efficiency.

Primers

Primers are lot-qualified by DNA sequencing using the dideoxy chain termination technique.

One Shot® TOP10 Chemically Competent *E. coli*

One Shot® TOP10 Chemically Competent cells are tested for transformation efficiency using the control plasmid included in the kit. Transformed cultures are plated on LB plates containing 100 µg/ml ampicillin and the transformation efficiency is calculated. Test transformations are performed in duplicate. Transformation efficiency should be greater than 1×10^9 cfu/µg plasmid DNA.

In addition, untransformed cells are tested for the appropriate antibiotic sensitivity and lack of phage contamination.

References

Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989) Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. J. Biol. Chem. *264*, 8222-8229

Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994) *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley-Interscience, New York

Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985) A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. Cell *41*, 521-530

Brownstein, M. J., Carpten, J. D., and Smith, J. R. (1996) Modulation of Non-Templated Nucleotide Addition by *Taq* DNA Polymerase: Primer Modifications that Facilitate Genotyping. BioTechniques *20*, 1004-1010

Cole, C. N., and Stacy, T. P. (1985) Identification of Sequences in the Herpes Simplex Virus Thymidine Kinase Gene Required for Efficient Processing and Polyadenylation. Mol. Cell. Biol. *5*, 2104-2113

Coloma, M. J., Hastings, A., Wims, L. A., and Morrison, S. L. (1992) Novel Vectors for the Expression of Antibody Molecules Using Variable Regions Generated by Polymerase Chain Reaction. J. Imm. Methods *152*, 89-104

Gurtu, V., Yan, G., and Zhang, G. (1996) IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochem. Biophys. Res. Comm. *229*, 295-298

Kaufman, R., Wasley, L., Spiliotes, A., Gossels, S., Latt, S., Larsen, G., and Kay, R. (1985) Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase in Chinese hamster ovary cells. Mol Cell Biol *5*, 1750-1759

Kozak, M. (1987) An Analysis of 5´-Noncoding Sequences from 699 Vertebrate Messenger RNAs. Nucleic Acids Res. *15*, 8125-8148

Kozak, M. (1990) Downstream Secondary Structure Facilitates Recognition of Initiator Codons by Eukaryotic Ribosomes. Proc. Natl. Acad. Sci. USA *87*, 8301-8305

Kozak, M. (1991) An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control. J. Cell Biology *115*, 887-903

Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987) Negative and Positive Regulation by a Short Segment in the 5´-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. Molec. Cell. Biol. *7*, 4125-4129

Rees, S., Coote, J., Stables, J., Goodson, S., Harris, S., and Lee, M. (1996) Bicistronic vector for the creation of stable cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques *20*, 102-110

Shuman, S. (1991) Recombination Mediated by Vaccinia Virus DNA Topoisomerase I in *Escherichia coli* is Sequence Specific. Proc. Natl. Acad. Sci. USA *88*, 10104-10108

Shuman, S. (1994) Novel Approach to Molecular Cloning and Polynucleotide Synthesis Using Vaccinia DNA Topoisomerase. J. Biol. Chem. *269*, 32678-32684

Werner, R. (2005) The development and production of biopharmeceuticals: technology and economic success factors. Bioprocess International *September*, 6-15

Pluronic® is a registered trademark of BASF Corporation

©2006 Invitrogen Corporation. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

Notes

Notes